Literature DB >> 8228763

Ovarian cancer and ABO blood groups.

J Henderson1, V Seagroatt, M Goldacre.   

Abstract

OBJECTIVE: To determine whether the distribution of ABO blood groups in women with ovarian cancer differs from that in the general population in a large, defined English region.
DESIGN: Analysis of record abstracts of hospital care held in the Oxford record linkage study supplemented with data from the Oxford cancer registry.
SETTING: Oxford Regional Health Authority area.
SUBJECTS: A total of 1261 women who had ovarian cancer between 1968 and 1986 with ABO blood groups recorded on the Oxford Record Linkage Study and cross checked against the cancer registry comprised the study group.
MEASUREMENTS AND MAIN RESULTS: The relative incidence of A:O and B:O blood groups in women with ovarian cancer were compared with the general population in the same region. Ovarian cancer was more common in women of blood group A than in others, with a relative incidence of 1.17. In particular, adenocarcinomas were the most common type of tumour and were associated with blood group A. The association was more striking in married women than in single women probably reflecting differences associated with parity.
CONCLUSION: The association between ABO blood groups and ovarian cancer found in this English population is similar in size to that reported from several other populations. Childbearing is known to reduce the risk of ovarian cancer and our findings suggest that the blood group association may be most apparent in married, parous (that is, relatively low risk) women.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8228763      PMCID: PMC1059794          DOI: 10.1136/jech.47.4.287

Source DB:  PubMed          Journal:  J Epidemiol Community Health        ISSN: 0143-005X            Impact factor:   3.710


  8 in total

1.  THE ABO BLOOD GROUPS IN NEOPLASTIC DISEASE OF THE OVARY.

Authors:  R H OSBORNE; F V DEGEORGE
Journal:  Am J Hum Genet       Date:  1963-12       Impact factor: 11.025

2.  The woman at risk for developing ovarian cancer.

Authors:  L McGowan; L Parent; W Lednar; H J Norris
Journal:  Gynecol Oncol       Date:  1979-06       Impact factor: 5.482

3.  Ovarian neoplasms, functional ovarian cysts, and oral contraceptives.

Authors:  M Vessey; A Metcalfe; C Wells; K McPherson; C Westhoff; D Yeates
Journal:  Br Med J (Clin Res Ed)       Date:  1987-06-13

Review 4.  Ovarian and cervical cancer.

Authors:  C Williams
Journal:  BMJ       Date:  1992-06-06

5.  Blood group distribution in women with ovarian cancer.

Authors:  E Björkholm
Journal:  Int J Epidemiol       Date:  1984-03       Impact factor: 7.196

6.  Tumours in Iceland. 9. Malignant tumours of the ovary. A histological classification, epidemiological considerations and survival.

Authors:  O Bjarnason; H Tulinius
Journal:  Acta Pathol Microbiol Immunol Scand A       Date:  1987-07

7.  Case-control study of ovarian cancer in Japan.

Authors:  M Mori; H Kiyosawa; H Miyake
Journal:  Cancer       Date:  1984-06-15       Impact factor: 6.860

8.  Genetic predisposition to cancer.

Authors:  B A Ponder
Journal:  Br J Cancer       Date:  1991-08       Impact factor: 7.640

  8 in total
  21 in total

1.  Relative Risk of Various Head and Neck Cancers among Different Blood Groups: An Analytical Study.

Authors:  Khushboo Singh; Sunder Kote; Basavaraj Patthi; Ashish Singla; Shilpi Singh; Hansa Kundu; Swati Jain
Journal:  J Clin Diagn Res       Date:  2014-04-15

Review 2.  Blood group antigens: molecules seeking a function?

Authors:  P Greenwell
Journal:  Glycoconj J       Date:  1997-02       Impact factor: 2.916

3.  ABO and Rh blood groups in patients with cholelithiasis and carcinoma of the gall bladder.

Authors:  M Pandey; A Gautam; V K Shukla
Journal:  BMJ       Date:  1995-06-24

4.  Association of ABO Blood Group and Rh factor with Periodontal Disease in a Population of Virajpet, Karnataka: A Cross-Sectional Study.

Authors:  S Vivek; Jithesh Jain; Sequiera Peter Simon; Hemanth Battur; S Supreetha; Reshmi Haridas
Journal:  J Int Oral Health       Date:  2013-08-28

5.  Is there a predictive significance of ABO blood group on chemotherapy-induced thrombocytopenia in patients with stage III colon cancer?

Authors:  Ozgur Tanriverdi
Journal:  Med Oncol       Date:  2014-11-27       Impact factor: 3.064

6.  ABO blood group and incidence of epithelial ovarian cancer.

Authors:  Margaret A Gates; Brian M Wolpin; Daniel W Cramer; Susan E Hankinson; Shelley S Tworoger
Journal:  Int J Cancer       Date:  2010-03-22       Impact factor: 7.396

7.  ABO blood group and risk of epithelial ovarian cancer within the Ovarian Cancer Association Consortium.

Authors:  Elizabeth M Poole; Margaret A Gates; Brigit A High; Stephen J Chanock; Daniel W Cramer; Julie M Cunningham; Brooke L Fridley; Simon A Gayther; Ellen L Goode; Edwin S Iversen; Jolanta Lissowska; Rachel T Palmieri Weber; Paul D P Pharoah; Catherine M Phelan; Susan J Ramus; Joellen M Schildkraut; Rebecca Sutphen; Ya-Yu Tsai; Jonathan Tyrer; Robert A Vierkant; Nicolas Wentzensen; Hannah P Yang; Kathryn L Terry; Shelley S Tworoger
Journal:  Cancer Causes Control       Date:  2012-09-08       Impact factor: 2.506

8.  Is ABO blood group a risk or prognostic factor for patients with endometrioid endometrial cancer? A retrospective analysis in Germany.

Authors:  Georgios Gitas; Louisa Proppe; Ibrahim Alkatout; Dimitrios Tsolakidis; Achim Rody; Christos Kotanidis; Sascha Baum
Journal:  Blood Transfus       Date:  2020-06-04       Impact factor: 3.443

9.  ABO blood group system and gastric cancer: a case-control study and meta-analysis.

Authors:  Zhiwei Wang; Lei Liu; Jun Ji; Jianian Zhang; Min Yan; Jun Zhang; Bingya Liu; Zhenggang Zhu; Yingyan Yu
Journal:  Int J Mol Sci       Date:  2012-10-17       Impact factor: 5.923

10.  Correlation between "ABO" blood group phenotypes and periodontal disease: Prevalence in south Kanara district, Karnataka state, India.

Authors:  Gurpur Prakash Pai; Mundoor Manjunath Dayakar; Mulki Shaila; Anitha Dayakar
Journal:  J Indian Soc Periodontol       Date:  2012-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.